WuXi XDC and Celltrion, Inc. announced that they have signed a Memorandum of Understanding (MOU) for comprehensive and integrated services which refer to the development, and manufacturing of bioconjugates include antibody-drug conjugates (ADCs). Under the collaboration, Celltrion will delegate WuXi XDC as primary service provider on each of the integrated projects, from process development to GMP manufacturing, within the global territory. WuXi XDC will be strategic service partner to support Celltrion's innovative pipeline advances, providing comprehensive services from process development to one-stop GMP manufacturing, aiming to accelerate the development of ADCs at a fast speed and with high quality.